Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
American Journal of Clinical Dermatology
|
November 11, 2025
Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials
Brian S Kim, Margarida Gonçalo, Tsukasa Ugajin, et al.
Dermatology and Therapy
|
March 19, 2026
Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria
Gil Yosipovitch, Brian S Kim, John Y Koo, et al.
Advances in Therapy
|
May 29, 2025
Prurigo Nodularis PaTient-Reported BurdEn of SicKness (PN TREK): A Cross-Sectional Survey of Patient-Reported Burden of Disease in Patients with PN from the US
Shawn G Kwatra, Min Yang, Bruno Martins, et al.
Dermatology and Therapy
|
May 12, 2026
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis
Sonja Ständer, Gil Yosipovitch, Shawn G Kwatra, et al.
Dermatology and Therapy
|
November 22, 2025
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria
Gil Yosipovitch, Brian S Kim, John Y Koo, et al.
Dermatology and Therapy
|
March 2, 2026
Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies
Shawn G Kwatra, Sonja Ständer, Brian S Kim, et al.
Journal of the American Academy of Dermatology
|
May 29, 2025
Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of 3 clinical trials
Amy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 24, 2024
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
Shawn G Kwatra, Gil Yosipovitch, Sonja Ständer, et al.
The British Journal of Dermatology
|
June 23, 2026
Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study
Konstantin Agelopoulos, Leigh Nattkemper, Felix Witte, et al.
Genome Biology
|
April 18, 2015
Expansion of a novel endogenous retrovirus throughout the pericentromeres of modern humans
Joseph Zahn, Mark H Kaplan, Sabrina Fischer, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
American Journal of Clinical Dermatology
|
November 11, 2025
Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials
Brian S Kim, Margarida Gonçalo, Tsukasa Ugajin, et al.
Dermatology and Therapy
|
March 19, 2026
Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria
Gil Yosipovitch, Brian S Kim, John Y Koo, et al.
Advances in Therapy
|
May 29, 2025
Prurigo Nodularis PaTient-Reported BurdEn of SicKness (PN TREK): A Cross-Sectional Survey of Patient-Reported Burden of Disease in Patients with PN from the US
Shawn G Kwatra, Min Yang, Bruno Martins, et al.
Dermatology and Therapy
|
May 12, 2026
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis
Sonja Ständer, Gil Yosipovitch, Shawn G Kwatra, et al.
Dermatology and Therapy
|
November 22, 2025
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria
Gil Yosipovitch, Brian S Kim, John Y Koo, et al.
Dermatology and Therapy
|
March 2, 2026
Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies
Shawn G Kwatra, Sonja Ständer, Brian S Kim, et al.
Journal of the American Academy of Dermatology
|
May 29, 2025
Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of 3 clinical trials
Amy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 24, 2024
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
Shawn G Kwatra, Gil Yosipovitch, Sonja Ständer, et al.
The British Journal of Dermatology
|
June 23, 2026
Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study
Konstantin Agelopoulos, Leigh Nattkemper, Felix Witte, et al.
Genome Biology
|
April 18, 2015
Expansion of a novel endogenous retrovirus throughout the pericentromeres of modern humans
Joseph Zahn, Mark H Kaplan, Sabrina Fischer, et al.
Page
of 3